Gianmarco has extensive experience in biomedical research, having worked in academia and the pharmaceutical industry. He began his career in 2010 as a research assistant in neuropharmacology at the UK branch of Eli Lilly and Co., focusing on drug discovery research for Alzheimer’s and Parkinson’s diseases. Subsequently, he joined the Telethon Institute of Genetics and Medicine (TIGEM) in Italy, where he explored novel molecular therapy approaches for treating brain pathology in patients with rare genetic disorders, specifically Lysosomal Storage Disorders.

In 2019, Gianmarco completed his PhD training at the Institute for Research in Biomedicine (IRB) in Barcelona, focusing his research on the molecular organisation of the HP1c transcription complex.

Alongside his research, Gianmarco gained experience managing projects focused on science, society, innovation, and scientific excellence within and beyond the EU Horizon 2020 framework.